Technologies
PDF


WARF: P07404US

Synthetic Ligands Capable of Strongly Inhibiting or Inducing Quorum Sensing in Bacteria


INVENTORS -

Helen Blackwell, Grant Geske, Jennifer Campbell Butler

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a powerful new class of chemical probes that are capable of strongly inhibiting or inducing quorum sensing.
OVERVIEWQuorum sensing is a process used by some bacteria to coordinate behavior based on local population density. To communicate, bacteria release signaling molecules, including low molecular weight ligands like acyl-homoserine lactones (AHL), into the environment. When a certain number of signaling molecules accumulates and the population reaches a sufficient density, the bacteria change their behavior to work together for a common goal. For example, they may adapt to the nutrients that are currently available, defend against other microorganisms or protect themselves from toxic compounds.

Agents that interfere with quorum sensing signals may reduce the virulence of certain types of pathogenic bacteria. When bacteria cannot work together to coordinate their attack, the likelihood of infection decreases.  However, few synthetic modulators of quorum sensing are known.
THE INVENTIONUW-Madison researchers have developed non-native ligands that can block or imitate quorum sensing signals.  The ligands include N-phenylacetanoyl-L-homoserine lactones that are capable of inhibiting or strongly inducing quorum sensing in the bacterial symbiont Vibrio fischeri.  The invention also includes methods of using the synthetic ligands to treat infections or modulate biofilm formation.
APPLICATIONS
  • Inhibiting quorum sensing bacteria to treat infections or reduce biofilm formation
  • Promoting beneficial bacterial activity, such as the formation of biofilms for use in bioremediation
  • Studying quorum sensing and its role in host-bacteria interactions
KEY BENEFITS
  • Provides a synthetic, super-agonist of quorum sensing
  • Simple structural modifications can transform potent quorum sensing antagonists into quorum sensing agonists.
  • Active in vivo
  • Because quorum sensing inhibitors have virulence-attenuating but not cell-killing effects, they do not select for drug resistance in bacteria and are likely to remain effective for longer periods of time.
ADDITIONAL INFORMATION
For More Information About the Inventors
Publications
  • Geske G.D.,O’Neill J.C. and Blackwell H.E. 2007. N-Phenylacetanoyl-L-Homoserine Lactones Can Strongly Antagonize or Super-Agonize Quorum Sensing in Vibrio fischeri. ACS Chem. Biol. 2, 315-320.
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.